Saxo-Market-Call_Platform_1920x1280_Test 5

The 800 pound long bond gorilla remains in the room.

Podcast 19 minutes to read
Saxo Logo
Saxo Market Call

Summary:  Today, an attempt to root out the sources of yesterday's ugly bout of risk off, with sovereign debt markets quite possibly driving much of the unease as several countries saw new cycle highs in 30-year yields. We also break down the reaction, if inconsistent, across currencies to new stresses in bond markets as we await key US labor market data while the market doesn't know what data to trust. This and more on today's pod, which is hosted by Saxo Global Head of Macro Strategy John J. Hardy.


Listen to the full episode now or follow the Saxo Market Call on your favorite podcast app.

Today’s links

My latest FX Update - focusing especially on the big blowout in long yields.

The incredible election maths for the UK if the election were held today - is Reform the government in waiting?

A helpful listener passed along a recent Australia in the World podcast episode with an interview of Brad Satser, talking Trump tariff,s, China and “Australia’s position in a fraying economic order”. Australia straddles the most difficult of fault-lines in whatever new world order is emerging, with so much of its economy dependent traditionally on Chinese demand (commodities from iron ore and coking coal to foodstuffs, etc.) while its historic security and cultural orientation is very much with the UK and US.

A company I have never heard of before that was a noted addition to Stanley Druckenmiller’s Duquesne family office fund in Q2 was Viking Therapeutics, a biotech company that IPO’ed back in 2015 and has yet to post a single cent of revenue, which is expected to come rolling in somewhere in 2027 if all goes as hoped. The company’s pipeline looks interesting, especially as a possible player in GLP-1 medications in pill form. Here’s a ChatGPT summary of the company. As the Motley Fool article notes, Druck’s move into this company could be about protecting existing investments in obesity care, or as an asymmetric upside play if the company becomes a takeover candidate or even as a go-it-alone play if they get FDA approval for one or more of their drugs - though the base case rests on the GLP-1 pill. More below. I was surprised to learn that a couple of other big players went not just years, but decades before becoming consistently profitable companies as go-it-along pharma companies - Regeneron and Vertex Pharmaceuticals.

Chart of the Day - Viking Therapeutics (VKTX)

The company (as noted above one that legendary trader and investor Stanley Druckenmiller’s family office fund added to its positions in Q2) has a market cap of USD 3.1 billion after its recent 42% single-day drop after its GLP-1 obesity pill, which if approved would eventually compete head-to-head with future pill-form obesity treatments from Eli Lilly and Novo Nordisk, saw results some found less impressive than hoped. It rocketed from lows near 2 dollars a share in late 2022 to nearly 100 dollars a share by early 2024 on the hype around obesity treatment made available by those two companies, a hype that has since faded as the pace of growth in the injectable GLP-1 market has disappointed. The company has other drugs more advanced in the US approval process with smaller addressable markets.

 

03_09_2025_VKTX
Source: Saxo

Questions and comments, please!

We invite you to send any questions and comments you might have for the podcast team. Whether feedback on the show's content, questions about specific topics, or requests for more focus on a given market area in an upcoming podcast, please get in touch at marketcall@saxobank.com.

This content is marketing material and should not be considered investment advice. Trading financial instruments carries risks and historic performance is not a guarantee for future performance.

The instrument(s) mentioned in this content may be issued by a partner, from which Saxo receives promotion, payment or retrocessions. While Saxo receives compensation from these partnerships, all content is conducted with the intention of providing clients with valuable options and information.

Quarterly Outlook

01 /

  • Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Quarterly Outlook

    Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    Quarterly Outlook

    Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    John J. Hardy

    Global Head of Macro Strategy

    After the chaos of Q2, the quarter ahead should get a bit more clarity on how Trump 2.0 is impacting...
  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details. Past Performance is not indicative of future results.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992